The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Hypermethioninemias of genetic and non‐genetic origin: A review
Abstract
This review covers briefly the major conditions, genetic and non‐genetic, sometimes leading to abnormally elevated methionine, with emphasis on recent developments. A major aim is to assist in the differential diagnosis of hypermethioninemia. The genetic conditions are: (1) Homocystinuria due to cystathionine β‐synthase (CBS) deficiency. At least 150 different mutations in the CBS gene have been identified since this deficiency was established in 1964. Hypermethioninemia is due chiefly to remethylation of the accumulated homocysteine. (2) Deficient activity of methionine adenosyltransferases I and III (MAT I/III), the isoenzymes the catalytic subunit of which are encoded by MAT1A. Methionine accumulates because its conversion to S‐adenosylmethionine (AdoMet) is impaired. (3) Glycine N‐methyltrasferase (GNMT) deficiency. Disruption of a quantitatively major pathway for AdoMet disposal leads to AdoMet accumulation with secondary down‐regulation of methionine flux into AdoMet. (4)S‐adenosylhomocysteine (AdoHcy) hydrolase (AHCY) deficiency. Not being catabolized normally, AdoHcy accumulates and inhibits many AdoMet‐dependent methyltransferases, producing accumulation of AdoMet and, thereby, hypermethioninemia. (5) Citrin deficiency, found chiefly in Asian countries. Lack of this mitochondrial aspartate–glutamate transporter may produce (usually transient) hypermethioninemia, the immediate cause of which remains uncertain. (6) Fumarylacetoacetate hydrolase (FAH) deficiency (tyrosinemia type I) may lead to hypermethioninemia secondary either to liver damage and/or to accumulation of fumarylacetoacetate, an inhibitor of the high K m MAT. Additional possible genetic causes of hypermethioninemia accompanied by elevations of plasma AdoMet include mitochondrial disorders (the specificity and frequency of which remain to be elucidated). Non‐genetic conditions include: (a) Liver disease, which may cause hypermethioninemia, mild, or severe. (b) Low‐birth‐weight and/or prematurity which may cause transient hypermethioninemia. (c) Ingestion of relatively large amounts of methionine which, even in full‐term, normal‐birth‐weight babies may cause hypermethioninemia. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Sassa, S., & Kappas, A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110809 · Cited by 145 · cited 1×
“Succinylacetone may play a prominent role in episodes of porphyria-like peripheral neuropathy due to its profound inhibition of delta-aminolevulinic acid dehydratase, thereby blocking heme biosynthesis [Sassa and Kappas, 1983].”
BackgroundHereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 1×
“Liver samples from various areas contained fumarylacetoacetate activities ranging from 6 to 32 mmol/min in one patient and 0.4– 4mmol/min in another (control range 33–66 mmol/min) [Kvittingen et al., 1993].”
BackgroundInfluentialCloning and expression of murine S-adenosylmethionine synthetase
Sakata, S. F., Shelly, L. L., Ruppert, S., Schutz, G., & Chou, J. Y. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85198-0 · Cited by 75
Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1
Santra, S., & Baumann, U. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1229 · Cited by 68 · cited 2×
“Treatment of FAH deficiency has been reviewed recently [Ashorn et al., 2006; McKiernan, 2006; Santra and Baumann, 2008].”
BackgroundMethodDemers, S. I., Russo, P., Lettre, F., & Tanguay, R. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00406-4 · Cited by 67
Cited by
Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease
Murphy, S. K., Yang, H., Moylan, C. A., Pang, H., Dellinger, A., Abdelmalek, M. F., Garrett, M. E., Ashley–Koch, A., Suzuki, A., Tillmann, H. L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.047 · Cited by 391
Guidelines for the diagnosis and management of cystathionine beta‐synthase deficiency
Morris, A. A. M., Kožich, V., Santra, S., Andria, G., Ben‐Omran, T. I. M., Chakrapani, A. B., Crushell, E., Henderson, M. J., Hochuli, M., Huemer, M., et al. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9979-0 · Cited by 340
Huemer, M., Diodato, D., Schwahn, B., Schiff, M., Bandeira, A., Benoist, J., Burlina, A., Cerone, R., Couce, M. L., Garcia‐Cazorla, A., et al. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9991-4 · Cited by 324
Parkhitko, A. A., Jouandin, P., Mohr, S. E., & Perrimon, N. (2019) · Aging Cell · doi:10.1111/acel.13034 · Cited by 275
Metadata
- Authors
- Mudd, S. H.
- Venue
- American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Publisher
- Wiley
- Published
- 2011-02-09
- Volume
- 157
- Issue
- 1
- Pages
- 3-32
- ISSN
- 1552-4868 (ISSN-L)
- 1552-4876
- OpenAlex
- W2134655304
- Cited by
- 181
- References
- 7
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypermethioninemias of genetic and non‐genetic origin: A review. https://app.cochat.ai/papers/10.1002/ajmg.c.30293
- The paper
- Mudd, S. H. (2011). Hypermethioninemias of genetic and non‐genetic origin: A review. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.30293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.